Contineum Therapeutics (CTNM) Competitors $13.50 +0.15 (+1.12%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends CTNM vs. MESO, TVTX, NTLA, PRAX, ARVN, ARDX, DAWN, SYRE, CALT, and SNDXShould you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Mesoblast (MESO), Travere Therapeutics (TVTX), Intellia Therapeutics (NTLA), Praxis Precision Medicines (PRAX), Arvinas (ARVN), Ardelyx (ARDX), Day One Biopharmaceuticals (DAWN), Spyre Therapeutics (SYRE), Calliditas Therapeutics AB (publ) (CALT), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry. Contineum Therapeutics vs. Mesoblast Travere Therapeutics Intellia Therapeutics Praxis Precision Medicines Arvinas Ardelyx Day One Biopharmaceuticals Spyre Therapeutics Calliditas Therapeutics AB (publ) Syndax Pharmaceuticals Contineum Therapeutics (NASDAQ:CTNM) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, community ranking, earnings, analyst recommendations and valuation. Does the media favor CTNM or MESO? In the previous week, Mesoblast had 13 more articles in the media than Contineum Therapeutics. MarketBeat recorded 16 mentions for Mesoblast and 3 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.63 beat Mesoblast's score of 0.57 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesoblast 6 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CTNM or MESO more profitable? Mesoblast's return on equity of 0.00% beat Contineum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Contineum TherapeuticsN/A -49.92% -20.52% Mesoblast N/A N/A N/A Does the MarketBeat Community believe in CTNM or MESO? Mesoblast received 403 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 70.33% of users gave Mesoblast an outperform vote. CompanyUnderperformOutperformContineum TherapeuticsOutperform Votes7100.00% Underperform VotesNo VotesMesoblastOutperform Votes41070.33% Underperform Votes17329.67% Do institutionals & insiders hold more shares of CTNM or MESO? 1.4% of Mesoblast shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable earnings & valuation, CTNM or MESO? Contineum Therapeutics has higher revenue and earnings than Mesoblast. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContineum Therapeutics$50M6.96$22.72MN/AN/AMesoblast$5.90M283.03-$87.96MN/AN/A Do analysts rate CTNM or MESO? Contineum Therapeutics presently has a consensus price target of $29.25, suggesting a potential upside of 116.67%. Mesoblast has a consensus price target of $13.50, suggesting a potential downside of 7.72%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Contineum Therapeutics is more favorable than Mesoblast.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Mesoblast 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryContineum Therapeutics and Mesoblast tied by winning 7 of the 14 factors compared between the two stocks. Ad ProsperityPubThis Indicator called BOTH NVDA ralliesRarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. Get Contineum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTNM vs. The Competition Export to ExcelMetricContineum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$348.00M$6.57B$5.14B$9.08BDividend YieldN/A2.98%5.09%4.23%P/E RatioN/A10.5089.8217.18Price / Sales6.96195.801,116.21116.95Price / Cash11.4557.1642.8937.86Price / Book-3.635.094.784.78Net Income$22.72M$151.83M$120.23M$225.60M7 Day Performance-3.78%-2.13%-1.92%-1.23%1 Month Performance-5.86%-3.10%11.49%3.36%1 Year PerformanceN/A11.54%30.57%16.60% Contineum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTNMContineum Therapeutics1.9558 of 5 stars$13.50+1.1%$29.25+116.7%N/A$348.00M$50M0.0031News CoverageHigh Trading VolumeMESOMesoblast1.0377 of 5 stars$12.10+2.9%$11.50-5.0%+590.1%$1.38B$5.90M0.0080Analyst ForecastOptions VolumeNews CoveragePositive NewsTVTXTravere Therapeutics2.7678 of 5 stars$17.49+1.0%$22.62+29.3%+106.0%$1.37B$145.24M-3.81460Positive NewsNTLAIntellia Therapeutics4.2166 of 5 stars$13.36+3.6%$54.94+311.2%-58.9%$1.36B$36.28M-2.46600PRAXPraxis Precision Medicines2.4033 of 5 stars$72.06+2.7%$146.33+103.1%+323.0%$1.34B$2.45M-7.06110Gap DownHigh Trading VolumeARVNArvinas2.031 of 5 stars$19.00-2.6%$63.50+234.2%-49.3%$1.31B$78.50M-4.18445ARDXArdelyx3.6907 of 5 stars$5.39+3.3%$10.42+93.3%-18.9%$1.28B$251.85M-17.80267DAWNDay One Biopharmaceuticals1.6211 of 5 stars$12.63-0.9%$35.71+182.8%-7.7%$1.27B$101.95M-12.3860SYRESpyre Therapeutics1.77 of 5 stars$24.46+1.4%$51.50+110.5%+53.4%$1.26B$890,000.00-3.23100CALTCalliditas Therapeutics AB (publ)0.065 of 5 stars$40.00-0.4%$39.25-1.9%N/A$1.19B$1.60B-21.62180SNDXSyndax Pharmaceuticals3.952 of 5 stars$13.77-1.1%$37.64+173.3%-33.6%$1.18B$16M-3.84110News Coverage Related Companies and Tools Related Companies MESO Competitors TVTX Competitors NTLA Competitors PRAX Competitors ARVN Competitors ARDX Competitors DAWN Competitors SYRE Competitors CALT Competitors SNDX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTNM) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTNM Stock Alerts